ERBB2 and cancer: Differences in disease-free survival between screen-detected luminal and aggressive cancers (HER2 + and TN) disappeared after adjustment for the Ki-67 tumor proliferation marker, which suggests that tumor aggressiveness is mediated by more rapid cell turnover reflected by Ki-67.